Pipeline In Alzheimer’s, Bristol Myers sees big promise beyond amyloid BioPharma DiveBristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work.NeuroscienceRead full story pharminent May 21, 2026 (Last updated: May 21, 2026) BioPharma Dive Bristol Myers’ neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work. Neuroscience Read full story Post navigation Previous: Lilly’s triple agonist shows bariatric surgery-like weight loss resultsNext: Gilead Sciences completes Tubulis acquisition for $5bn Related Stories Pipeline Chasing Dupixent, a biotech aims to make better antibody drugs for eczema pharminent August 11, 2026 Pipeline Epicrispr lands $90M to advance epigenetic editing drug for rare muscle disease pharminent August 11, 2026 Pipeline BioMarin axes asset from $270M Inozyme takeover, ending run in rare metabolic indication pharminent August 10, 2026
